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Abstract: 
 
In the pre-targeted therapy era, palliative cytoreductive nephrectomy combined with 
cytokine immunotherapy was the standard treatment protocol for the management of 
metastatic renal cell carcinoma. The introduction of targeted therapies has improved 
response rates, median survival and overall prognosis when compared to immunotherapy. 
The role of cytoreductive nephrectomy in providing an independent survival advantage 
when used alongside immunotherapy has been demonstrated by two randomised controlled 
trials. However, with the new shift in improved treatment outcomes from cytokine 
immunotherapy to targeted therapies, the continuing role of cytoreductive nephrectomy as 
a viable surgical treatment modality remains controversial. 
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Introduction: 
 
Renal cell carcinoma (RCC) is the 12th most common cancer worldwide and the third 
leading cause of mortality amongst genitourinary malignancies, representing a significant 
health burden [1]. In 2012, RCC was associated with an annual incidence of 338,000 cases 
globally and a mortality rate of 2% [2]. Interestingly, despite the increase of incidental 
carcinomas detected on radiological imaging approximately, 25% of patients with RCC 
present with metastases at the time of diagnosis[3]. Furthermore, between 20-40% of 
patients undergoing nephrectomy for localised RCC will go on to develop metastatic 
disease [4].Historically, patients with disseminated disease had a dismal prognosis with an 
estimated 5 year survival rate of less than 5% and a median survival time of 6 to 10 months 
[5]. Over the last decade with the advent of novel targeted therapies 5 year survival rates 
have increased modestly to 8% [1]. 
 
In the pre-targeted therapy era, evidence based on two significant prospective randomised 
trials confirmed the role of cytoreductive nephrectomy (CN) in the management of 
metastatic RCC (m-RCC) in conjunction with adjuvant immunotherapy. Proposed benefits 
of CN include debulking of the primary tumour which acts to stimulate the immune system 
to control residual disease as well as removal of the source of potential new metastases[6].  
 
In the past two decades the von-Hippel-Lindau (VHL) gene, a tumour suppressor gene has 
been identified as an important step in renal carcinogenesis. A loss of VHL function, results 
in the accumulation of hypoxia-inducible factor (HIF), culminating in increased expression 
of pro-angiogenic growth factors including vascular endothelial growth factor (VEGF), 
epidermal growth factor (EGF) and pigment epithelial derived factor (PEDF). These 
growth factors result in increased cell proliferation, survival and angiogenesis [7]. Thus, 
inhibition of growth factor signalling pathways, by the introduction of targeted therapies 
represents a novel strategy in the management approach tom-RCC. The efficacy of targeted 
therapies has been evaluated within numerous randomised phase III trials [8,9,10,11]. 
Overall, prolonged median survival and reduced toxicity when compared to 
immunotherapy, have helped establish its central role in treatment protocols[12]. Whether 
a continuing surgical approach to m-RCC management fits into this new treatment 
paradigm and translates into improved treatment outcomes remains to be elucidated. 
 
Role of targeted therapy in metastatic renal cell carcinoma: 
 
Currently licensed targeted therapies approved for use in m-RCC include three multi-
targeted TKI’s: sunitinib, sorafenib and paopanib as well as newer more potent 
agentsaxitnib and tivozanib. Other targeted agents include VEGF monoclonal antibody, 
known as bevacizumab and mammalian target of rapamycin (mTOR) inhibitor, 
temsorilimus and everolimus [13].  
 
By exploiting the molecular differences between tumour cells and healthy tissues, these 
agents offer a targeted tumour response resulting in improved treatment outcomes when 
compared to immunotherapy. Despite variations in treatment and tolerability outcomes, 
most randomised phase III trials reveal superior response rates, progression free survival 
(PFS) and overall survival (OS)[8,9,10,11].Sunitinib demonstrated a therapeutic advantage 
over INF-α2b with PFS of 26.4 months compared to 21.8 months[8].Sorafenib, a raf kinase 
and VEGF inhibitor, revealed superior outcomes in OS when compared to placebo in 
patients with cytokine refractory m-RCC (17.3 months vs 14.8 months respectively) [9]. 
Disappointingly bevacizumab, used in combination with INF-α2b, offered marginal 
prolonged OS when compared with INF-α2b alone with a median duration of 18.3 months 
and 17.4 months, respectively which was not statistically significant. [10].Similarly, 
although temsirolmus demonstrated superior OS compared to INF-α2b alone (10.9months 
vs 7.3 months)this was only observed on secondary analysis [11]. 
 
These agents are generally considered relatively safe, associated with improved adverse 
effect profile compared to cytokine therapy including toxicity related effects as well as 
systemic symptoms including fever, loss of appetite, malaise and diarrhoea [12]. Moreover, 
targeted therapies have demonstrated equally efficacious treatment outcomes when using 
lower doses of cytokine therapy as a combined treatment strategy, thereby improving 
overall safety and tolerability outcomes [13]. 
 
Overall, the introduction of targeted therapies have largely superseded immunotherapy 
within the metastatic setting. Despite superior outcomes associated with targeted therapies 
patient response rates remain modest from 10-15% to up to 40%, translating into marginal 
improvements in 5 year survival rates [14].Unfortunately their clinical response is not 
permanent and time to progression of disease is on average between 6-12 months 
[15].Furthermore, it is important to bear in mind the majority of participants receiving 
systemic therapy, may also have undergone prior CN, thus the survival benefit conferred 
by such therapies may not be independent of its use [16]. In addition, the primary endpoints 
assessed in such trials were objective parameters such as OS and PFS. However, 
prolongation of survival without an associative improvement in the health related quality 
of life (HRQL) although clinically advantageous, may not be valued by every patient and 
their families. HRQL outcomes and patients perception of positive treatment outcomes 
often directly impact on patient’s decision to continuing further care. As a clinical being 
mindful of such factors is a key principal when counselling patients on therapeutic options 
available [17].  
 
Role of cytoreductive nephrectomy in metastatic renal cell carcinoma: 
 
The exact pathophysiological mechanisms explaining the rationale of CN in treatment 
protocols remain unclear. Primarily, CN is thought to result in a significant reduction in 
disease burden and development of new metastasis, thereby extending the time to lethal 
tumour metastasis. 
 
Elucidation of renal cell carcinogenesis reveals it is essentially an immunogenic tumour 
manipulating the function of the immune system, resulting in suppression of the anti-
tumour effect exhibited by our defence mechanism. During this process the primary tumour 
is believed to resist exogenous growth inhibitory signals, evade apoptosis and recruit 
angiogenic factors signals, whilst diverting the circulating immune system away from 
metastatic sites to avoid immunosurveillence [18] Numerous mechanistic properties of CN 
have been proposed including removal of these pro-angiogenic factors and removal of 
suppression of immunological factors which manipulate residual disease [19]. 
 
Studies have also described CN to result in a low grade systemic acidosis, acting to disrupt 
the tumour microenvironment and halting metastatic growth [20].Cellular mechanisms 
aside, CN can result in symptomatic benefit in multiple ways. These include pain relief, 
management of intractable haematuria, uncontrolled hypertension as well as control of 
refractory hypercalcaemia [21]. The psychological impact of removing the primary tumour 
may also improve HRQL and perception of positive treatment outcomes [22]. 
 
Interestingly, early reports demonstrated that up to 1% of patient’s experienced 
spontaneous regression of metastatic disease following CN. Despite this promising finding, 
further studies suggest it to be a fortuitous event [6]. Due to the rarity of such cases the 
pathophysiological mechanisms responsible for regression remain unclear and indeed 
identifying potential candidates for regression, impossible. However it has been speculated 
that spontaneous regression may result in removal of growth factors secreted by the tumour 
as well as promotion of apoptosis [23]. 
 
Cytoreductive therapy in the era of cytokine immunotherapy: 
 
To date, two prospective randomised trials comparing CN and adjuvant immunotherapy 
versus immunotherapy alone, support the multidisciplinary paradigm of performing CN 
for the management of m-RCC. In 2001, the European Organisation for the Research and 
Treatment of Cancer (EORTC)study compared palliative nephrectomy alongside INF-α 
immunotherapy with INF-α monotherapy in m-RCC patients. Patients randomised to 
undergo surgical intervention had an independent survival benefit when compared to 
immunotherapy with a median duration of survival of 17 months and 7 months, 
respectively. Furthermore, PFS was prolonged in nephrectomised patients to 5 months 
compared to 3 months in those receiving immunotherapy alone[24]. Outcomes from a 
larger trial of 241 participants, led by the Southwest Oncology group (SWOG 8949) 
demonstrated a less pronounced 3 month median survival advantage in participants who 
underwent CN prior to INF-α2b therapy with a median survival of 11.1 months compared 
to 8 months in participants receiving INF-α2b therapy alone [25].  
 
A pooled analysis of both the EORTC and SWOG trials led by Flanigan et al reported 
overall median survival was superior in CN with INF-α2b at 13.6 months compared to 7.8 
months with INF-α2b alone[26].Of note, the difference in median survival was 
independent of pre-defined clinical variables such asPS, metastatic site and presence or 
absence of metastatic lesion. Following the original publication, data based on a 9 year 
follow-up concluded superior OS of 11 months versus 8 months in patients undergoing CN 
compared to immunotherapy alone. The hazard ratio in nephrectomised patients was 0.74, 
representing a 26% reduction in death. Interestingly, the hazard ratio in these patients when 
categorised according to PS, metastatic site and presence of metastatic lesion was also less 
than 1, supporting the author’s recommendation of performing CN in all surgically 
appropriate candidates [27].Whether prognostic factors identified in the immunotherapy 
era will be similar within the targeted therapy setting is debatable and requires further 
investigation. Currently the CARMENA trial assessing CN with 
adjuvantsunitinibversussunitinib monotherapy is underway where it is hoped assessment 
of pre-defined clinical factors would provide conclusive information on predicting 
treatment outcomes [28].  
 
Drawbacks and limitations of these historic trials have led to controversy regarding the 
ongoing role of CN in m-RCC management. Firstly, a disproportionate number of patients 
with PS1 were assigned to the immunotherapy treatment arm compared to the CN arm, 
58.9% and 46.6% respectively [29]. PS 1 is associated with an invariably worse prognosis 
compared to PS 0, with a study led by Elson et al revealing a median survival of 6.7 months 
compared to 10.1 months, respectively [30]. Secondly, both trials were significantly 
underpowered throwing the validity of their results and the conclusions drawn into question. 
Thirdly, the eligibility criteria required patients to have a PS of 0 or 1 along with evidence 
of resectable primary tumour. As a result, the data is limited regarding patients with 
unresectable primary tumour, widely disseminated disease or multiple metastases [29]. 
Although these shortcomings cloud the continuing role of CN, numerous, albeit 
retrospective studies, support the widely held opinion that CN remains beneficial in the 
treatment of m-RCC. A Cochrane based analysis concluded that in appropriately selected 
surgical patients with m-RCC, CN prior to immunotherapy provides the best survival 
strategy [31].  
 
Cytoreductive nephrectomy in the era of targeted therapy: 
 
The benefit derived from CN alongside newly developed targeted therapies remains 
unclear. Current evidence is based on non-randomised trials which appear promising, 
suggesting a possible survival advantage. A recent meta-analysis of 11 non-randomised 
trials evaluated a total of 39,953 patients with advanced RCC revealing patients treated 
with CN in addition to targeted therapies had a 54% reduced risk of death compared to 
targeted therapy alone [32]. One of the largest retrospective studies based on the SEER 
national database of 20,104 patients led by Conti et al revealed overall survival advantage 
of 19 months versus 4 months in favour of patients who underwent CN [33].Such 
improvements in survival benefit have been mirrored in studies varying from large national 
databases to large multicentre case series. Importantly, the benefit of CN was confirmed in 
a multivariate analysis adjusting for clinicopathological variables including age, PS and 
other biochemical parameters [32].  
 
Currently no study has prospectively validated the role of CN when added to targeted 
therapies and as such current guidelines do not provide definitive recommendations for its 
use. Consequently, over the last decade there has been an increasing trend in the use of 
targeted therapies whilst CN adoption has fallen. A study by Psutka et al revealed the 
annual rate of targeted therapy utilisation from 2004-2010 increased from 10% to 98.2%.  
Comparatively the utilisation of CN has decreased in half from 30% to 15% with some 
clinicians calling for a purely systemic approach to m-RCC management in the absence of 
level I evidence[34]. 
 
Many argue the morbidity associated with a procedure of unknown efficacy which has the 
potential to delay targeted therapy, known to derive clinical benefit to be unacceptable. In 
a retrospective study of 30 nephrectomised patients only 23% of patients underwent 
systemic therapy post-operatively, whilst progression of disease, surgical morbidity and 
mortality precluded 77% of patients from receiving systemic therapy [35]. Although this 
was an extremely small case series it is important to develop criteria to ascertain which 
patients would benefit from CN prior to systemic therapy. Consistent with this, studies 
exploring prognostic factors associated with m-RCC suggest time from diagnosis to 
treatment to be the most significant predictive factor in determining OS [36].  
 
Currently it remains unclear whether patients of all risk disease groups benefit from CN, 
however retrospective evidence suggests CN results in reduced risk of death even in poor 
risk groups although not to the same extent as favourable risk groups. Ultimately this may 
result in selection bias firstly, in identifying patients with favourable predictive factors, 
whom are likely to derive maximum clinical benefit and improved post-operative outcomes 
as potential candidates for surgery. Secondly, in selecting patients who respond positively 
to systemic therapy and exhibit stable disease as surgical candidates, avoiding those with 
early progressive disease associated with an invariably worse prognosis and treatment 
outcomes [37]. 
 
Patient selection in cytoreductive nephrectomy: 
 
The identification of prognostic factors that allow patient risk stratification prior to CN is 
important, not only in selecting patients who would most likely derive a therapeutic 
advantage but also to effectively counsel patients prior to treatment, optimise post-
operative recovery and maximise systemic therapy. Several prognostic models have been 
developed including the Memorial Sloan Kettering Cancer Centre (MSKCC) model which 
utilises independent predictors of poor outcomes such as elevated LDH, increased 
corrected calcium, low serum haemoglobin, low PS score and increased time from 
diagnosis to initiation of therapy[38]. Patients are subsequently categorised in risk groups 
and in a study led by Motzer, the comparative median survival outcome in patients with 
poor versus favourable risk were 4 and 20 months, respectively [39].  
 
Post-operative factors likely to impact on treatment outcomes have also been explored. The 
percentage of tumour removed; known as the fractional percentage of tumour volume 
removed (FPTV) has been found to be an independent predictor of PFS when the median 
FPTV is 95% [40]. Fallick et al demonstrated reduction of >75% of overall tumour burden 
was required to be beneficial [41].  
 
There is also progress in studies aiming to identify patients with poor risk who may benefit 
from avoiding the potential morbidity and mortality associated with surgery and commence 
targeted therapy earlier. In a large retrospective study comparing pre-operative outcomes 
in patients undergoing CN or systemic monotherapy, Culp et al identified seven pre-
operative negative predictors of survival. These include low serum albumin, high serum 
LDH, clinical tumour classification of T3 or T4 disease, symptoms at presentation caused 
by metastatic disease, presence of liver metastasis and radiological evidence of 
retroperitoneal or supra-diaphragmetic lymphadenopathy at time of CN.  They concluded 
patients who had more than 4 risk factors did not benefit from CN versus systemic therapy 
alone [42]. 
 
Recently the eligibility criteria for CN patient selection has undergone re-evaluation, 
incorporating important determinants of adverse outcomes such as PS, number of 
metastatic sites, presence of nodal disease and histological sub-type [43]. Whether these 
factors continue to remain relevant in the era of targeted therapies remains unclear. 
Outcomes from the CARMENA trial may address this ambiguity and aid the development 
of selection criteria specific to targeted therapy.  
 
 
Below is a table summarising the major randomised control studies in m-RCC  
 
Author, study and no 
of participants 
 
Study trial Objective Outcomes 
Motzer et al, 2007 
Phase III RCT 
750 participants 
TKI vs INF Sunitinib vs INFα- 2b  4.6 month OS benefit  
Survival advantage of 26.4 months vs 
21.8 months 
Rini et al, 2010 
Phase III RCT 
732 participants 
VEGFI vs 
INF 
Bevicazumab + INFα-
2b vs INFα-2b alone 
0.9 month OS benefit 
Survival advantage of 18.3 months vs 
17.4 months. Not statistically 
significant 
Escudier et al, 2009 
Phase III RCT 
903 participants 
TKI vs INF 
 
Sorafenib vs placebo 3.5 month OS benefit  
Survival advantage of 17.8 months vs 
14.3 months 
Hudes et al, 2007 
Phase III RCT 
626 participants 
mTORI vs 
mTORI+INF
vs INF alone 
 
Temsirolimusvs 
temsirolimus+ INF a-
2b vs INFα-2balone 
3.6 month OS benefit- observed only 
on secondary analysis of OS 
Survival advantage of 10.9 months vs 
8.4 vs 7.3 months 
Mickisch et al, 2001 
Phase III RCT 
85 participants 
CN+INF vs 
INF alone 
EORTC  
CN + INFα-2b vs 
INFα-2b  alone 
10 month OS benefit.  
Survival advantage of 17 months vs 7 
months 
Flanigan et al, 2001 
Phase III RCT 
246 participants 
CN+ INF vs 
INF alone 
SWOG-8949 
CN + INFα-2b vs 
INFα-2b monotherapy  
3 month OS benefit. 
Survival advantage of 11 months vs 8 
months  
Flanigan et al, 2004 
Phase III RCT 
331 participants 
CN+ INF vs 
INF alone 
SWOG and EORTC 
combined analysis 
5.8 month OS benefit 
Survival advantage of 13.6 months vs 
7.8 months 
Mejean et al, ongoing 
Phase III RCT 
Recruiting 
CN+ TKI vs 
TKI alone 
CARMENA- trial 
CN + sunitinib vs 
sunitinibalone 
Ongoing 
Bex et al, ongoing 
Phase III RCT 
Recruting 
CN+TKI  SURTIME trial 
Immediate versus 
deferred CN + 
sunitinib 
Ongoing 
VEGFI = vascular endothelial growth factor inhibitor, mTORI = mammalian target of 
rapamycin inhibitor 
 
Advances in cytoreductive nephrectomy: 
 
Over the last two decades advancements in surgical techniques have significantly reduced 
post-operative morbidity rates associated with CN. Minimally invasive techniques such as 
laparoscopic CN (LCN) have grown in popularity since its initial description in 1991 by 
Clayman et al [44]. Traditionally, open nephrectomy in the setting of m-RCC was 
associated with significant morbidity, delaying or potentially precluding patients from 
receiving systemic immunotherapy which can result in disease progression, particularly 
CNS metastases [45].The application of a minimally invasive approach can hasten 
recovery, shortening the interval before commencing therapy [46]. Furthermore, reported 
studies of LCN have consistently demonstrated favourable outcomes including reduced 
postoperative pain, shorter hospital stay and a shorter period of rehabilitation when 
compared to open nephrectomy. In a study from the National Cancer Institute, patients who 
underwent LCN had a shorter duration of recovery time, expediting the administration of 
immunotherapy compared with those undergoing open CN [47]. Consistent with this, data 
from the Cleveland Clinic concluded LCN resulted in a shorter hospital stay of 2.3 days 
compared to 6.1 days associated with an open approach and a notable shorter interval prior 
to initiation of system therapy of 36 vs 61 days [48]. In a case series of 11 patients Walther 
et al also described a lower analgesia requirement associated with the laparoscopic 
approach when compared with a similar cohort who underwent conventional open 
nephrectomy [49].  
 
Overall, it appears that fears of CN precluding patients from systemic therapy may be less 
relevant in the era of targeted therapies and minimally invasive surgical (MIS) 
interventions. However, despite current evidence demonstrating superiority of MIS over 
open techniques, CN trials including SWOG and EORTC have only utilised open 
approaches. Thus further large scale randomised trials powered to compare treatment 
outcomes of MIS with systemic therapy are warranted. 
 
Timing of cytoreductive nephrectomy: 
 
Concerns over propagating metastatic disease progression by delaying targeted therapy 
post CN, has raised questions of commencing systemic therapy in the neo-adjuvant setting. 
Neoadjuvant targeted therapy paradigms are common practice for many other malignancies 
including those of the gastrointestinal tract, thyroid and breast [50]. Advantages of neo-
adjuvant targeted therapy primarily include down-staging/sizing of an unresectable 
primary tumour, facilitating subsequent surgical resection with fewer complications and 
allowing targeted patient selection, differentiating poor responders from those exhibiting a 
positive clinical response or stable disease whom in turn would respond favourably to 
surgical resection [51]. A further advantage of delayed CN is that upon surgical resection, 
histology specimens may be taken to evaluate the exact biological mechanisms responsible 
for positive clinical response to systemic targeted therapy. This can serve to enhance our 
understanding of the precise mechanistic properties of targeted therapies and their effect 
on the progression of m-RCC [52]. Currently a retrospective study evaluating patients 
treated with deferred CN have higher treatment response rates when compared to 
immediate CN with a response rate of 12% and a median survival of 14 months compared 
to 8% and 12 months in the latter group [53]. Interestingly, current systemic therapy 
protocols are based on cytokine immunotherapy which have no biological effect on the 
primary tumour. It is hoped prospective randomised data collated from the SURTIME trial 
would shed light on the interplay of targeted therapy of delayed CN and its impact on OS 
and PFS [54]. 
 
Disadvantages of delayed CN include concerns that targeted therapies may potentiate 
surgical morbidity by obviating proangiogenic properties associated with inhibiting VEGF 
and other signalling pathways. This can lead to impaired microvasculature increasing the 
likelihood of post-operative bleeding and thromboembolic events. Furthermore these 
pathways play a vital role in tissue integrity with subsequent disruption leading to an 
increase in impaired wound healing rates and incisional hernia incidence. Withholding 
systemic therapy for at least 2-3 half life cycles prior or post-surgery may help preserve 
microvasculature and tissue integrity and reduce adverse effects. However there are no 
randomised studies demonstrating this and limited data exists on the safety profile of 
delayed CN and targeted therapy as a combined treatment strategy[55]. Retrospective data 
including a small case series of 19 patients undergoing delayed CN revealed this treatment 
paradigm to be generally safe and well tolerated with low morbidity rates. Although a 
larger retrospective study examining the side effect profile of delayed CN in 44 patients 
observed a high complication rate of 39% however most were minor and mirrored 
morbidity of patients undergoing initial surgical resection [56]. Overall, evidence from 
retrospective data support the integration of delayed CN and targeted therapies in 
appropriately selected patients. Prognostic factors and PS have an important role in 
determining which patients are most likely to benefit from this treatment paradigm.  
 
Role of metastectomy in m-RCC 
 
Recently, small trials have demonstrated CN alongside metastasectomy in selected patients 
with low volume m-RCC positively impact on survival outcomes. A trial led by Eggener 
et al demonstrated surgical resection of metastatic foci yielded improved long term disease 
free survival in 44 patients[57]. Consistent with these findings Alt et al found the absence 
of complete metastasectomy was associated with significant three-fold increase risk of 
death with a hazard ratio of 2.91 and thus concluded complete resection of macroscopic 
metastases should be considered in surgically appropriate candidates [58]. Findings from 
a systematic review identified eight studies comparing complete metastasectomy, 
incomplete metastasectomy or no metastasectomy. There was a significant longer term 
median survival associated with complete metastasectomy compared to no metastasectomy 
with a median of 40.8 months versus 14.8 months respectively. Assessment of hazard ratios 
unequivocally favoured complete metastasectomy in all eight studies [59]. Although, 
current evidence favours metastasectomy as a treatment approach to m-RCC the benefit of 
targeted therapy use post-metastasectomy requires further evaluation.  
 
Role of nephron sparing surgery (NSS) in m-RCC 
 
The role of nephron sparing surgery (NSS) has recently been evaluated for the management 
of m-RCC in individuals where preservation of renal function is pertinent.  Interestingly, a 
study, albeit small sample size comparing NSS with CN in patients with m-RCC found 
comparable survival benefit [60]. However the sample size was small and thus it would be 
difficult to derive clinical meaningful outcomes. A more recent study evaluating patients 
undergoing NSS compared to CN with renal cortical tumours, demonstrated a superior 
median survival advantage of 5.1 years and 3 years respectively, This advantage could 
partly be explained by the preservation of renal function in NSS, whereas CN can lead to 
deteriorating renal function and the subsequent complications associated with the 
development of chronic kidney disease [61]. 
 
In future it will be interesting to assess how the interplay between targeted therapies and 
the combination of metastasectomy and CN versus CN alone or CN versus NSS compare 
in response rates, PFS and OS outcomes. Notably each surgical intervention has its own 
eligibility criteria for patient selection which involves incorporating varying prognostic 
factors relevant to each modality. This in turn could be affected when combined with 
targeted therapy. 
 
Role of combined targeted therapy in m-RCC 
 
Targeting separate pathways involved in renal cell carcinogenesis have been postulated to 
maximise treatment outcomes allowing patients to derive the full benefits of treatment. The 
potential of synergistic antitumor effects with combined therapy has been evaluated in a 
phase I study assessing sunitinib in combination with tremelimumab an anti CTLA-4 
antibody within the metastatic setting. Of 21 patients, 9 achieved a partial tumour response 
however it resulted in unacceptable toxic outcomes including acute renal failure and will 
not be further evaluated [62].A larger prospective study of 63 patients treated with 
bevacizumab and erlotinib, targeting EGF revealed 25% exhibited positive treatment 
responses. The authors proposed the efficacy of combined treatment was superior to either 
drug alone, owing to targeting of multiple signalling pathways [63]. Unfortunately 
development of this study with the addition of imatinib to bevaciumb/erlotinib proved to 
increase grade ¾ toxicities including diarrhoea, rash and fatigue [64].Vaccines in 
conjunction with targeted therapies are also being explored. Findings from a phase II study 
evaluating a dendritic cell based vaccine AGS-003 with sunitinib compared with sunitinib 
monotherapy illustrate superior PFS (11.9 months versus 8 months respectively). 
Importantly no added toxicity was observed [65]. 
 
Overall, the potential benefit of combined treatment strategies with complementary 
mechanism of action support the use of targeted therapies in combination with 
immunotherapies, vaccines and T-cell modulating agents. Although emerging evidence of 
early phase clinical trials appear promising, clinicians must be mindful of the potential 
toxicity of combined regimens [66].  
 
Conclusion: 
 
CN alongside adjuvant cytokine immunotherapy is a well-established treatment protocol 
in the management of m-RCC, demonstrating independent significant survival advantage 
when compared to immunotherapy alone. Since the 1990’s the introduction of tumour 
targeted therapies have resulted in modest improvements in patient survival when 
compared to cytokine immunotherapy. Advancements in surgical techniques and 
procedures, coupled with manipulation of targeted therapy dosing regimens and combined 
therapeutic strategies have further optimised treatment outcomes and prolonged OS. 
However current response rates have improved modestly resulting in marginal 
improvements in 5 year mortality rates. Furthermore PFS remains temporary with evidence 
of tumour progression between 6-12 months. 
 
With continuing innovation, the role of CN within the metastatic setting will no doubt 
change in the foreseeable future. Whether CN continues to play a role in m-RCC 
management in the targeted therapy era or whether it is superseded by targeted therapy 
alone remains to be evaluated in randomised prospective trials. Questions will likely arise 
on the appropriate timing of CN and how this would affect prognostic factors used to 
identify surgically appropriate candidates. Current evidence based on non-randomised 
retrospective trials are promising however outcomes of the CARMENA and SURTIME 
trial are eagerly anticipated to advance this evidence base. Until then given current 
retrospective evidence of the beneficial role of CN alongside immunotherapy, CN should 
not be abandoned but still be considered as a viable therapeutic strategy in carefully 
surgically selected patients.  
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Abbreviations: 
 
RCC- renal cell carcinoma 
m-RCC- metastatic renal cell carcinoma 
VHL-von Hippel Lindau 
EGF- epidermal growth factor 
PEGF-pigment epithelial derived factor 
VEGF-vascular endothelial growth factor 
HIF-hypoxic inducible factor 
CN-cytoreductive nephrectomy 
TKI-tyrosine kinase inhibitor 
m-TOR-mammalian target of rapamycin 
INF- interferon 
PFS-progression free survival 
OS-overall survival 
PS-performance status 
RTC- randomised controlled trial 
FPTV-fractional percentage of tumour volume removed  
HRQL-health related quality of life 
EORTC-European Organisation for the Research and Treatment of Cancer  
SWOG-southwest oncology group 
MSKCC-Memorial Sloan Kettering Cancer Centre  
LDH: lactate dehydrogenase 
LCN-laparascopiccytoreductive nephrectomy 
MIS-minimally invasive surgery 
NSS-nephron sparing surgery 
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